NCT05389423View on ClinicalTrials.gov

Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas

PHASE1RecruitingINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

June 27, 2023

Primary Completion Date

June 1, 2028

Study Completion Date

June 1, 2032

Conditions
Diffuse Large Cell LymphomaNon-Hodgkin LymphomaBurkitt LymphomaPlasmablastic LymphomaB-Cell Neoplasm
Interventions
DRUG

Vincristine

0.4 mg/m2/day administered by CIVI on days 1 to 4

DRUG

Prednisone

60 mg/m2/day administered orally on days 1 to 5

DRUG

Doxorubicin

10 mg/m2/day administered by CIVI on days 1 to 4

DRUG

Etoposide

50 mg/m2/day administered by CIVI on days 1 to 4

DRUG

Pomalidomide

An initial dose of 3mg administered orally for 10 days in all cycles. In cycle 1, it will start 5 days before DA-EPOCH; in cycles 2-6, it will start on day 1. Administered at an MTD dose for the expansion phase.

DRUG

Cyclophosphamide

750 mg/m2 administered IV on day 5

DRUG

Rituximab

375 mg/m2 administered IV on day 1 (only for CD20+ tumors)

Trial Locations (1)

20892

RECRUITING

National Institutes of Health Clinical Center, Bethesda

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH